Objective-To investigate the effect of cyclosporin A (CyA) therapy on circulating concentrations of interleukin-6 (IL-6) and soluble interleukin-2 receptor (sIL-
decrease was accompanied by an improvement in clinical parameters of disease activity. Some association between sIL-2R, IL-6, haemoglobin, and platelets was also observed. Conclusions-This study has demonstrated that, in vivo, CyA therapy in RA can significantly reduce circulating concentrations of IL-6 and sIL-2R. Modulation of both T and non-T cell derived cytokines may be one mechanism by which CyA improves rheumatoid disease. Whether this is a direct effect of CyA on the cells within the rheumatoid joint producing these cytokines or an indirect effect mediated by other cytokines which can influence IL-6 and I1-2R values remains to be determined. ( calculated against a preparation of recombinant IL-6 (88/1540, National Institute of Biological Standards and Control, UK, kindly donated by Dr A Meager) and expressed in IU/ml, 1 unit being equivalent to the amount of IL-6 required to yield 50% proliferation of the cells. Assay specificity was assessed by neutralisation studies. The bioassay inter and intra assay variation were 19% and 14%, respectively, with a detection limit of 0<15 IU/ml.
MEASUREMENT OF SOLUBLE IL-2 RECEPTOR
A commercially available enzyme linked immunoassay using two non-competing murine monoclonal antibodies to Tac protein of the human IL-2 receptor was used (T Cell Sciences Inc., Lab-Impex, UK). The inter and intra assay variations were 5% and 3%, respectively. The limit of detection was 50 U/ml. IL-6 concentrations decreased by a median value of 57% after treatment (fig 1) . The median concentration of IL-6 before treatment (165 (9-1567) IU/ml) decreased significantly (to 71 (4-559) IU/ml) (p=0 02). Of the 24 patients included in this study, 11 had a greater than 50% reduction in their plasma IL-6. Those with a greater than 50% decrease in plasma IL-6 concentrations did not differ from the remainder in their clinical indices.
SERUM SOLUBLE IL-2 RECEPTOR
The median concentration before treatment of 665 (50-3200) U/ml decreased significantly to 570 (170-2160) U/ml (p = 0.001) (fig 2) . CyA treatment resulted in a median decrease of 29% in sIL-2R concentrations after 16 weeks. Of the 24 patients, only three had greater than 50% reduction in their sIL-2R concentrations and these patients did not differ from the others in their clinical indices. Effects of cyclosporin A on interleukin-6 and soluble interleukin-2 receptor in patients with rheumatoid arthritis Studies in vitro have demonstrated a synergistic effect between IL-6 and other cytokines in the induction of acute phase proteins.6 It is not clear if the decrease in IL-6 concentrations we observed was a direct effect of CyA on IL-6 production or reflected a reduction in IL-2 and sIL-2R expression; in vitro, the latter affects IL-6 secretion.7 Similarly, modulation by CyA of other inflammatory cytokines may be involved.
CyA caused a significant improvement in three indices of clinical disease. The absence of any effect on pain score despite a clear improvement in the extent of clinical joint inflammation is not easily explained except on the basis of sample size.
In conclusion this study showed a reduction in plasma sIL-2R and IL-6 after CyA therapy. Unlike other second line agents which appear to have a more specific effect, CyA appears capable of targeting both T and non-T cells. It is not clear if the reduction in IL-6 is a direct effect on macrophages or fibroblasts or caused by a reduction in other cytokines which modulate IL-6.
